A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa
調査の概要
詳細な説明
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 study to evaluate the efficacy and safety of TVP-1012 in Japanese participants with early Parkinson's disease.
The study period consisted of a 28-week trial period. The participants who fulfill the inclusion criteria and not meeting any of the exclusion criteria were enrolled, and randomized in a 1:1 ratio to either the 1 mg of TVP-1012 or the placebo group. In each treatment group, participants received either 1 mg of TVP-1012 or placebo once daily in a double-blinded manner.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
-
Akita、日本
-
Aomori、日本
-
Fukuoka、日本
-
Fukushima、日本
-
Hiroshima、日本
-
Kochi、日本
-
Kyoto、日本
-
Niigata、日本
-
Okayama、日本
-
Osaka、日本
-
Tokushima、日本
-
Toyama、日本
-
Wakayama、日本
-
Yamagata、日本
-
-
Aichi
-
Nagoya、Aichi、日本
-
-
Ehime
-
Matsuyama、Ehime、日本
-
Touon、Ehime、日本
-
-
Fukuoka
-
Kitakyushu、Fukuoka、日本
-
Onoshiro、Fukuoka、日本
-
-
Hokkaido
-
Asahikawa、Hokkaido、日本
-
Iwamizawa、Hokkaido、日本
-
-
Hyogo
-
Akashi、Hyogo、日本
-
Kobe、Hyogo、日本
-
-
Ibaragi
-
Tsuchiura、Ibaragi、日本
-
Tsukuba、Ibaragi、日本
-
-
Iwate
-
Morioka、Iwate、日本
-
-
Kagawa
-
Takamatsu、Kagawa、日本
-
-
Kanagawa
-
Fujisawa、Kanagawa、日本
-
Sagamihara、Kanagawa、日本
-
Yokohama、Kanagawa、日本
-
-
Kumamoto
-
Goushi、Kumamoto、日本
-
-
Miyagi
-
Sendai、Miyagi、日本
-
-
Nagano
-
Matsumoto、Nagano、日本
-
-
Nagasaki
-
Higashisonogi-gun、Nagasaki、日本
-
Nishisonogi-gun、Nagasaki、日本
-
-
Nara
-
Tenri、Nara、日本
-
-
Niigata
-
Jouetsu、Niigata、日本
-
-
Osaka
-
Higashiosaka、Osaka、日本
-
Suita、Osaka、日本
-
Takatsuki、Osaka、日本
-
Toyonaka、Osaka、日本
-
-
Saitama
-
Irima-gun、Saitama、日本
-
-
Shizuoka
-
Fuji、Shizuoka、日本
-
Hamamatsu、Shizuoka、日本
-
Izunokuni、Shizuoka、日本
-
-
Tochigi
-
Shimono、Tochigi、日本
-
-
Tokushima
-
Yoshinogawa、Tokushima、日本
-
-
Tokyo
-
Bunkyo-ku、Tokyo、日本
-
Fuchu、Tokyo、日本
-
Kodaira、Tokyo、日本
-
Meguro-ku、Tokyo、日本
-
Nerima-ku、Tokyo、日本
-
Ota-ku、Tokyo、日本
-
Setagaya-ku、Tokyo、日本
-
Shibuya-ku、Tokyo、日本
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Run-in period
- In the opinion of the investigator or sub-investigator, the participant is capable of understanding and complying with protocol requirements.
- The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
- The participant has a diagnosis of Parkinson's disease with at least two of the following signs: resting tremor, akinesia/bradykinesia, and muscle rigidity.
- The participant has a Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II + Part III total score of >=14 at the start of the run-in period.
- The participant has Modified Hoehn & Yahr stage 1 to 3 at the start of the run-in period.
- The participant has the Parkinson's disease diagnosed within 5 years prior to the start of the run-in period.
- The participant is an outpatient of either sex aged >= 30 and < 80 years.
- A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent to 1 month after the last dose of the investigational drug.
Treatment period
- The participant has a MDS-UPDRS Part II + Part III total score of >= 14 at baseline.
Exclusion Criteria:
Run-in period
- The participant has received any investigational medication within 90 days prior to the start of the run-in period.
- The participant has received TVP-1012 in the past.
- The participant is study site employee, an immediate family member, or in a dependent relationship with a study site employee who is involved in the conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.
- Participant has donated 400 mL or more of his or her blood volume within 90 days prior to the start of the run-in period.
- The participant has unstable systemic disease.
- The participant has Mini-Mental State Examination (MMSE) score of <= 24 at the start of the run-in period.
- The participant has known or a history of schizophrenia, major or severe depression, or any other clinically significant psychiatric disease.
- The participant has a history of hypersensitivity or allergies to TVP-1012 (including any associated excipients) or selegiline.
- The participant has a history of clinically significant hypertension or other reactions associated with ingestion of tyramine-rich food (e.g., cheese, lever, herring, yeast, horsebean, banana, beer or wine).
- The participant has a history or concurrent of drug abuse or alcohol dependence.
- The participant has received neurosurgical intervention for Parkinson's disease (e.g., pallidotomy, thalamotomy, deep brain stimulation).
- The participant has received transcranial magnetic stimulation within 6 months prior to the start of the run-in period
- The participant has received amantadine or anticholinergic medication for >= 180 days.
- The participant has received selegiline, a levodopa-containing product or dopamine agonist for >= 90 days.
- The participant has received selegiline, pethidine, tramadol, reserpine or methyldopa within 90 days prior to the start of the run-in period.
- The participant has received a levodopa-containing product, dopamine agonist, amantadine or anticholinergic drug within 30 days prior to the start of the run-in period.
- The participant has received any psychoneurotic agent or antiemetic medication of dopamine antagonist within 14 days prior to the start of the run-in period. However, the participant has been receiving quetiapine or domperidone with a stable dose regimen for >= 14 days prior to the start of the run-in period may be included in the study.
- The participant has previously received a catechol-O-methyltransferase (COMT) inhibitor, droxidopa, zonisamide or istradefylline.
- The participant is required to take any of the prohibited concomitant medications or treatments.
- If female, the participant is pregnant or lactating or intending to become pregnant during this study, or within 1 month after the last dose of the investigational drug; or intending to donate ova during such time period.
- The participant has clinically significant neurologic, cardiovascular, pulmonary, hepatic (including mild cirrhosis), renal, metabolic, gastrointestinal, urological, endocrine, or hematological disease.
The participant has clinically significant or unstable brain or cardiovascular disease, such as:
- clinically significant arrhythmia or cardiac valvulopathy,
- cardiac arrest of NYHA Class II or higher,
- concurrent or a history of ischemic cardiac disease within 6 months prior to the start of the run-in period,
- concurrent or a history of clinically significant cerebrovascular disease within 6 months prior to the start of the run-in period,
- sever hypertension (systolic blood pressure of 180 mmHg or higher, or diastolic blood pressure of 110 mmHg or higher),
- clinically significant orthostatic hypotension (including those with systolic pressure decrease of 30 mmHg or more following postural change from supine/sitting position to standing position),
- a history of syncope due to hypotension within 2 years prior to the start of the run-in period.
- The participant is required surgery or hospitalization for surgery during the study period
- Participant has a history of cancer within 5 years prior to the start of the run-in period, except cervix carcinoma in situ which has completely cured.
- The participant has acquired immunodeficiency syndrome (AIDS) [including human immunodeficiency virus (HIV) carrier], or hepatitis [including viral hepatitis carrier such as hepatitis B surface (HBs) antigen or hepatitis C antibody (HCV) positive]. However, the participant who has a negative result for HCV antigen or HCV-RNA can be included in the study.
- The participant who, in the opinion of the investigator or sub-investigator, is unsuitable for any other reason.
Treatment period
- The participant whose diagonosis of Parkinson's disease is ruled out by dopamine transporter scintigraphy performed during the run-in period if conducted.
The participant has laboratory data meeting any of the following at the start of the run-in period:
- Creatinine >= 2 x upper limit of normal (ULN)
- Total bilirubin >= 2 x ULN
- ALT or AST >= 1.5 x ULN
- ALP >= 3 x ULN
- The participant has received any of the prohibited concomitant medications or treatments during the run-in period.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:TVP-1012 1 mg
For 2 weeks during the run-in period, one tablet of placebo orally, once daily before or after breakfast, followed by 26 weeks during the treatment period, one tablet of TVP-1012 1 mg orally, once daily before or after breakfast.
|
TVP-1012 1mg Tablets
|
プラセボコンパレーター:Placebo
For 2 weeks during the run-in period, one tablet of placebo orally, once daily before or after breakfast, followed by 26 weeks during the treatment period, one tablet of placebo orally, once daily before or after breakfast.
|
プラセボ錠
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II + Part III Total Score
時間枠:From Baseline to Week 26 (LOCF)
|
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) retains the four-scale structure with a reorganization of the various subscale; (Part I; 13 items) non-motor experiences of daily living, (Part II; 13) motor experiences of daily living, (Part III; 34) motor examination, and (Part IV; 6) motor complications.
Each items had 0-4 ratings, where 0 (normal) to 4 (severe) and score for each was summed to calculate the total scores.
The scale range for Part II+III Total Score was 0-188, with higher scores reflecting greater severity.
|
From Baseline to Week 26 (LOCF)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
少なくとも1回の治療で緊急有害事象(TEAE)および重篤な有害事象(SAE)を経験した参加者の数
時間枠:26週目まで
|
26週目まで
|
|
バイタルサイン値が著しく異常な参加者の数
時間枠:26週目まで
|
26週目まで
|
|
臨床検査に関連するTEAE参加者数
時間枠:26週目まで
|
26週目まで
|
|
Change From Baseline in MDS-UPDRS Part I Total Score
時間枠:Baseline and Week 26 (LOCF)
|
For MDS-UPDRS Part I (non-motor experiences of daily living) scores, the scale range for Part I Total Score was 0-52, with higher scores reflecting greater severity.
|
Baseline and Week 26 (LOCF)
|
Change From Baseline in MDS-UPDRS Part II Total Score
時間枠:Baseline and Week 26 (LOCF)
|
For MDS-UPDRS Part II (motor experiences of daily living) scores, the scale range for Part II Total Score was 0-52, with higher scores reflecting greater severity.
|
Baseline and Week 26 (LOCF)
|
Change From Baseline in MDS-UPDRS Part III Total Score
時間枠:Baseline and Week 26 (LOCF)
|
For MDS-UPDRS Part III (motor examination) scores, the scale range for Part III Total Score was 0-132, with higher scores reflecting greater severity.
|
Baseline and Week 26 (LOCF)
|
Number of Participants With TEAE Related to Body Weight
時間枠:Up to Week 26
|
Up to Week 26
|
|
Number of Participants With TEAE Related to Electrocardiograms (ECG)
時間枠:Up to Week 26
|
Up to Week 26
|
協力者と研究者
スポンサー
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- TVP-1012/CCT-001
- U1111-1165-1302 (レジストリ識別子:WHO)
- JapicCTI-152760 (レジストリ識別子:JapicCTI)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IPD 共有アクセス基準
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
パーキンソン病の臨床試験
-
Adelphi Values LLCBlueprint Medicines Corporation完了肥満細胞性白血病 (MCL) | 攻撃的な全身性肥満細胞症 (ASM) | SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) | くすぶり全身性肥満細胞症 (SSM) | 無痛性全身性肥満細胞症 (ISM) ISM サブグループが完全に募集されましたアメリカ
プラセボの臨床試験
-
Palacky University完了
-
Universidade Federal do ParaConselho Nacional de Desenvolvimento Científico e Tecnológico完了
-
Advice Pharma Group srl積極的、募集していない肥満 | 栄養障害 | 体重 | 減量 | 食生活 | 太りすぎと肥満 | 健康行動 | ダイエット、健康 | ダイエット習慣 | ライフスタイル | 栄養、健康 | 行動障害イタリア
-
University Hospital, Strasbourg, France積極的、募集していない